Category: cancer biology

Cancer researcher in Germany loses multiple papers after misconduct finding

A pathology journal is retracting two papers after an investigation at the last author’s institution in Germany found evidence of scientific misconduct.

The notice for both papers cites an investigation involving Regine Schneider-Stock, who studies cancer biology at the Friedrich Alexander-University Erlangen-Nuremberg (FAU). Meanwhile, another 2005 paper that lists Schneider-Stock as the first author was retracted in October, noting evidence of image manipulation.

The most recent retractions, from the American Journal of Pathology, note that FAU declined to provide the journal with details of its investigation beyond a prepared statement:

Continue reading Cancer researcher in Germany loses multiple papers after misconduct finding

Journal cleans the house by retracting 6 cancer papers for plagiarism

Following an investigation, a genetics journal has pulled six cancer papers published this year for plagiarizing from other sources.

According to an excerpt from the retraction notice in Genetics and Molecular Research, the journal has “strong reason to believe that the peer review process was [a] failure,” and has alerted the authors’ institutions.

The notice announcing the retraction of all six papers begins: Continue reading Journal cleans the house by retracting 6 cancer papers for plagiarism

High-profile Science paper retracted for misconduct

Science has retracted a high-profile immunology paper after a probe concluded the corresponding author had committed misconduct.

The paper — which initially caught media attention for suggesting a protein could help boost the immune system’s ability to fight off tumors — has been under a cloud of suspicion since last year, when the journal tagged it with an expression of concern, citing a university investigation.

That investigation — at Imperial College London — has concluded that the paper contained problematic figures that were the result of research misconduct. All were prepared by last and corresponding author Philip Ashton-Rickardt, who took full responsibility. Even though the paper was published in 2015, some original blots and accompanying details have disappeared.

Today, the journal released a retraction notice: Continue reading High-profile Science paper retracted for misconduct

Journal pulls cancer paper that used others’ data; authors MIA

A journal has retracted a paper after a reader pointed out some of the data looked familiar — and the authors never responded to the allegations.

According to the retraction notice in the International Journal of Molecular Medicine, the reader showed the journal that the histological data in two of the figures were from another published paper by different researchers. But when the journal contacted the authors on several occasions, they didn’t hear back. 

Here’s the retraction notice: Continue reading Journal pulls cancer paper that used others’ data; authors MIA

Prominent cancer researcher committed nearly 30 acts of misconduct

An investigation into the lab of a prominent cancer researcher in British Columbia has revealed nearly 30 acts of misconduct.   

As we detail in our latest feature for Science, the investigation, at the University of British Columbia (UBC), uncovered 29 instances of scientific misconduct, 16 of which were characterized as “serious,” according to university correspondence obtained by Retraction Watch.

The researcher, Sandra Dunn, is prominent in her field, but she left UBC in 2015 under unclear circumstances, shortly after it concluded its investigation. Dunn now heads a private company, Phoenix Molecular Designs, which says it develops therapies for cancer patients and lists local charities among its “partners and supporters.” While at UBC, Dunn obtained at least $1.1 million dollars in Canadian federal funding, some of which was used to support the falsified studies.

To some of the people involved, the most unsettling part of the incident is that it appears Dunn still receives support from Canadian charities. Continue reading Prominent cancer researcher committed nearly 30 acts of misconduct

UCLA lab pulls two papers — one by author who admitted to misconduct

A lab at the University of California, Los Angeles has retracted two papers for duplicated images.

These retractions — in the Journal of Immunology — represent the second and third retractions for the lab head; he lost another paper after one of his former students confessed to manipulating images.

Although Eriko Suzuki admitted to her actions on PubPeer in 2014, the 2007 Oncogene paper wasn’t retracted until June, 2016, when the journal issued a notice citing “data irregularities.”

Unfortunately, Suzuki’s admission in 2014 wasn’t the end of the troubles for lab head Benjamin Bonavida, who recently issued two additional retractions in the Journal of Immunology, only one of which includes Suzuki as a co-author.

Bonavida told us the university received allegations (he’s not sure from who) that some of the control gels were duplicated; he didn’t agree, but couldn’t produce the original gels to disprove it. We asked if any more retractions were coming from Bonavida, who has since retired from running a lab:

Continue reading UCLA lab pulls two papers — one by author who admitted to misconduct

PubPeer wins appeal of court ruling to unmask commenters

Fazlul Sarkar

PubPeer is having a good day.

In a new ruling, a trio of judges on the Michigan Court of Appeals reversed a 2015 decision mandating the site reveal the identity of anonymous commenters after a scientist sued them, claiming they cost him a job offer.

The judges stated that Fazlul Sarkar, the scientist suing the commenters, can continue pursuing a defamation case, but: Continue reading PubPeer wins appeal of court ruling to unmask commenters

How a researcher’s request to correct one paper turned into 19 retractions

jcheng
Jin Cheng

Last year, a cancer researcher wrote to the Journal of Biological Chemistry, asking to correct one of his papers. The journal responded by requesting the raw data used to prepare his figures. Then, in a follow-up request, it asked for raw data behind the figures in 20 additional published articles.

And when all was said and done six months later, Jin Cheng ended up with far more than just a single correction: Last month, the journal issued withdrawals for 19 of his papers — including the paper he originally asked to correct — along with one correction.

We’ve pieced together some clues about what happened after reviewing correspondence between representatives of JBC and Moffitt Cancer Center, where Cheng conducted his research. A spokesperson for Moffitt confirmed that the retractions did not initiate from an institutional investigation — but that the institution is now conducting one.

That’s not the way retractions typically happen: Often, journals don’t have the resources to conduct investigations themselves, so institutions mostly take the lead in double-checking papers and, if necessary, contacting the journal to initiate a retraction. Here, it seems the opposite took place.

The Moffitt spokesperson also told us that Continue reading How a researcher’s request to correct one paper turned into 19 retractions

Nature Cell Biology retracts hotly debated cancer paper

ncbLast week, we learned a 2016 paper heavily discussed on PubPeer might be retracted — today, we learned that Nature Cell Biology has indeed pulled the paper, citing inappropriate image modifications.

As we reported last week, a comment on PubPeer flagged as coming from an author said they had requested a retraction. A representative of National Taiwan University (NTU) told us the first author had resigned, and the paper was under investigation — an investigation which included the last author, a prominent researcher who is also a vice president at another institution in Taiwan.

Here’s Nature Cell Biology‘s official statement about the paper, in the form of a retraction notice that appears to be written by the authors:  Continue reading Nature Cell Biology retracts hotly debated cancer paper

Two Harvard-led groups pull well-cited cancer papers for duplication

the-journal-of-clinical-investigationTwo sets of authors based largely at Harvard Medical School have each retracted a paper for duplication in the same journal.

Both papers — which are more than a decade old — were pulled in The Journal of Clinical Investigation on November 1 by their respective corresponding authors.

One paper’s last author told us it was difficult to identify how the duplications occurred since the study took place so long ago, but added that multiple experiments had corroborated the results.

Here’s the first retraction notice for “Complementary roles of IRS-1 and IRS-2 in the hepatic regulation of metabolism:” Continue reading Two Harvard-led groups pull well-cited cancer papers for duplication